JPRN-jRCT2080221281未知3 期
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Child-Pugh score of < 9 (Child-Pugh A or B [B7 or B8])
- •-BCLC stage C or BCLC B not amenable to locorrectional therapy or refractory to locoregional therapy.
- •-Diagnosis of HCC (excluding fibrolamellar carcinoma)
- •-The patient has received sorafenib as the most recent systemic therapeutic intervention.
- •-Adequate Organ Function
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Study of Ramucirumab and Best Supportive Care versus Placebo and Best Supportive care in patients with second line treatment advanced liver cancer after treatment with Sorafenib.MedDRA version: 14.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2010-019318-26-ATImClone LLC624
进行中（未招募）
不适用
A Study of Ramucirumab and Best Supportive Care versus Placebo and Best Supportive care in patients with second line treatment advanced liver cancer after treatment with Sorafenib.Hepatocellular CarcinomaEUCTR2010-019318-26-PTImClone LLC624
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib - REACHMedDRA version: 13.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular CarcinomaEUCTR2010-019318-26-NOImClone LLC565
进行中（未招募）
不适用
A Study of Ramucirumab and Best Supportive Care versus Placebo and Best Supportive care in patients with second line treatment advanced liver cancer after treatment with Sorafenib.MedDRA version: 16.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2010-019318-26-HUImClone LLC624
进行中（未招募）
不适用
A Study of Ramucirumab and Best Supportive Care versus Placebo and Best Supportive care in patients with second line treatment advanced liver cancer after treatment with Sorafenib.MedDRA version: 16.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864Hepatocellular CarcinomaEUCTR2010-019318-26-SEImClone LLC624